Teradyne (TER) Q1 2025 10-Q Quarterly Report
Filed: May 2, 2025Period ending Mar 30, 2025
Health Care
Instruments For Meas & Testing of Electricity & Elec SignalsSEC EDGAR Teradyne (TER) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 2, 2025 for the fiscal period ending Mar 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Teradyne Q1 2025 10-Q Analysis
Risk Factors
- • New restructuring risk due to Robotics go-to-market consolidation triggering $9.2M severance for ~150 employees
- • Most updated financial risk: Cash decreased by $102.3M to $621.5M, driven by $157.5M stock repurchases and $61.8M investing outflows
- • Regulatory risk: Adoption of ASU 2023-09 requires expanded income tax disclosures, effective fiscal 2025, with no operational impact expected
- • Operational risk: Robotics sales dropped 21.3% causing $23.2M income before tax decline, linked to market weakness in collaborative robotic arms
- • Market risk: Semiconductor Test revenue up 24.8% driven by mobility, shifting revenue mix to 79% from 72%, affecting near-term growth focus
Teradyne Q1 2025 Quarterly FinancialsXBRL
Revenue
$686M
▲ +14.3% YoY
Net Income
$99M
▲ +54.1% YoY
Net Margin
14.4%
▲ +372bp YoY
Source: XBRL data from Teradyne Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Teradyne Quarterly Reports
Get deeper insights on Teradyne
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.